146 related articles for article (PubMed ID: 38605958)
1. Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study.
Choi CH; Lee JW; Bae DS; Kang ES; Cho D; Kim YM; Kim K; Kim JW; Kim HS; Kim YT; Lee JY; Lim MC; Oh T; Song B; Jeon I; Park M; Kim WH; Kang CY; Kim BG
Front Immunol; 2024; 15():1371353. PubMed ID: 38605958
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
Choi CH; Choi HJ; Lee JW; Kang ES; Cho D; Park BK; Kim YM; Kim DY; Seo H; Park M; Kim W; Choi KY; Oh T; Kang CY; Kim BG
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31948126
[No Abstract] [Full Text] [Related]
3. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW; Hur SY; Woo JW; Kim YM; Lim MC; Park SY; Seo SS; No JH; Kim BG; Lee JK; Shin SJ; Kim K; Chaney MF; Choi YJ; Suh YS; Park JS; Sung YC
Lancet Oncol; 2020 Dec; 21(12):1653-1660. PubMed ID: 33271094
[TBL] [Abstract][Full Text] [Related]
4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.
Jung M; Lee JB; Kim HS; Kwon WS; Kim HO; Kim S; Park M; Kim W; Choi KY; Oh T; Kang CY; Chung HC; Rha SY
Cancer Res Treat; 2024 Jan; 56(1):208-218. PubMed ID: 37402409
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
Morris VK; Jazaeri A; Westin SN; Pettaway C; George S; Huey RW; Grinsfelder M; Shafer A; Johnson B; Vining D; Guo M; Fellman B; Frumovitz M
Oncologist; 2023 Jul; 28(7):618-623. PubMed ID: 37104874
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Aggarwal C; Saba NF; Algazi A; Sukari A; Seiwert TY; Haigentz M; Porosnicu M; Bonomi M; Boyer J; Esser MT; Cheng LI; Agrawal S; Jennings EC; Durham NM; Fraser K; Lissa D; Gong M; Ceaicovscaia N; Gascó Hernández A; Kumar R
Clin Cancer Res; 2023 Feb; 29(3):560-570. PubMed ID: 36455147
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ
J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
12. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
Huh WK; Brady WE; Fracasso PM; Dizon DS; Powell MA; Monk BJ; Leath CA; Landrum LM; Tanner EJ; Crane EK; Ueda S; McHale MT; Aghajanian C
Gynecol Oncol; 2020 Sep; 158(3):562-569. PubMed ID: 32641240
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
15. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract][Full Text] [Related]
16. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
17. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.
Massarelli E; William W; Johnson F; Kies M; Ferrarotto R; Guo M; Feng L; Lee JJ; Tran H; Kim YU; Haymaker C; Bernatchez C; Curran M; Zecchini Barrese T; Rodriguez Canales J; Wistuba I; Li L; Wang J; van der Burg SH; Melief CJ; Glisson B
JAMA Oncol; 2019 Jan; 5(1):67-73. PubMed ID: 30267032
[TBL] [Abstract][Full Text] [Related]
18. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.
Chiappori AA; Williams CC; Gray JE; Tanvetyanon T; Haura EB; Creelan BC; Thapa R; Chen DT; Simon GR; Bepler G; Gabrilovich DI; Antonia SJ
Cancer Immunol Immunother; 2019 Mar; 68(3):517-527. PubMed ID: 30591959
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.
An J; Li X; Wang J; Zhu L; An R; Jiang K; Huang Y; Wang K; Li G; Wang C; Yuan J; Hou X; Yang G; Li J; Wang Q; Zhu J; Wu L
Front Immunol; 2023; 14():1142256. PubMed ID: 37153587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
